Long-term follow-up data for Study 1540: Safety profile1

Adverse reactions in ≥10% of patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation and who received LIBTAYO in Study 15401

Chart, longer-term follow-up data in clinical study 1540: mCSCC or laCSCC (N=193)
  • Grade ≥3 adverse reactions occurred in 95 patients (49.2%). The most common Grade ≥3 adverse reactions were hypertension (n=9, 4.7%), anemia, cellulitis, and pneumonia (all n=8, 4.1%)1
  • *Adverse reactions reported in ≥10% of patients, ordered by frequency of any grade.1
  • Adapted with permission from Rischin et al, 2021.1
  • CSCC=cutaneous squamous cell carcinoma; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC.